Literature DB >> 29188799

Computational insights into the G-protein-biased activation and inactivation mechanisms of the μ opioid receptor.

Jian-Xin Cheng1,2, Tao Cheng1, Wei-Hua Li1, Gui-Xia Liu1, Wei-Liang Zhu2, Yun Tang1.   

Abstract

The μ opioid receptor (OR), a member of the class A subfamily of G-protein coupled receptors (GPCRs), is a major target for the treatment of pain. G-protein biased μ-OR agonists promise to be developed as analgesics. Thus, TRV130, the first representative μ-OR ligand with G-protein bias, has entered into phase III clinical trials. To identify the detailed G-protein-biased activation and inactivation mechanisms of the μ-OR, we constructed five μ-OR systems that were in complexes with the G-protein-biased agonists TRV130 and BU72, the antagonists β-FNA and naltrexone, as well as the free receptor. We performed a series of conventional molecular dynamics simulations and analyses of G-protein-biased activation and inactivation mechanisms of μ-OR. Our results, together with previously reported mutation results, revealed the operating mode of the activation switch composed of residues W6.48 and Y7.43 (Ballesteros/Weinstein numbering), the activity of which was responsible for down- and up-regulation, respectively, of the β-arrestin signaling, which in turn affected G-protein-biased activation of μ-OR. TRV130 was found to stabilize W6.48 by interacting with Y7.43. In addition, we obtained useful information regarding μ-OR-biased activation, such as strong stabilization of W7.35 through a hydrophobic ring interaction in the TRV130 system. These findings may facilitate understanding of μ-OR biased activation and the design of new biased ligands for GPCRs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29188799      PMCID: PMC5758664          DOI: 10.1038/aps.2017.158

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  47 in total

1.  Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation.

Authors:  Olaf Fritze; Sławomir Filipek; Vladimir Kuksa; Krzysztof Palczewski; Klaus Peter Hofmann; Oliver P Ernst
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-24       Impact factor: 11.205

2.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.

Authors:  Thomas A Halgren; Robert B Murphy; Richard A Friesner; Hege S Beard; Leah L Frye; W Thomas Pollard; Jay L Banks
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

3.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

Review 4.  Novel GPCR paradigms at the μ-opioid receptor.

Authors:  G L Thompson; E Kelly; A Christopoulos; M Canals
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

5.  Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges.

Authors:  K Vanommeslaeghe; E Prabhu Raman; A D MacKerell
Journal:  J Chem Inf Model       Date:  2012-11-28       Impact factor: 4.956

6.  Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.

Authors:  L M Bohn; R R Gainetdinov; F T Lin; R J Lefkowitz; M G Caron
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

7.  Morphine side effects in beta-arrestin 2 knockout mice.

Authors:  Kirsten M Raehal; Julia K L Walker; Laura M Bohn
Journal:  J Pharmacol Exp Ther       Date:  2005-05-25       Impact factor: 4.030

8.  Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.

Authors:  Claire L Neilan; Stephen M Husbands; Simon Breeden; M C Holden Ko; Mario D Aceto; John W Lewis; James H Woods; John R Traynor
Journal:  Eur J Pharmacol       Date:  2004-09-19       Impact factor: 4.432

9.  Molecular details of the activation of the μ opioid receptor.

Authors:  Jihyun Shim; Andrew Coop; Alexander D MacKerell
Journal:  J Phys Chem B       Date:  2013-06-24       Impact factor: 2.991

Review 10.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

View more
  11 in total

1.  The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats.

Authors:  C Austin Zamarripa; Shelley R Edwards; Hina N Qureshi; John N Yi; Bruce E Blough; Kevin B Freeman
Journal:  Drug Alcohol Depend       Date:  2018-09-18       Impact factor: 4.492

2.  Encoding mu-opioid receptor biased agonism with interaction fingerprints.

Authors:  R Bruno Hernández-Alvarado; Abraham Madariaga-Mazón; Fernando Cosme-Vela; Andrés F Marmolejo-Valencia; Adel Nefzi; Karina Martinez-Mayorga
Journal:  J Comput Aided Mol Des       Date:  2021-10-29       Impact factor: 3.686

Review 3.  Recent Molecular Insights into Agonist-specific Binding to the Mu-Opioid Receptor.

Authors:  Ferenc Zádor; Kornél Király; Nariman Essmat; Mahmoud Al-Khrasani
Journal:  Front Mol Biosci       Date:  2022-06-13

4.  Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.

Authors:  Huiqun Wang; Danni Cao; James C Gillespie; Rolando E Mendez; Dana E Selley; Lee-Yuan Liu-Chen; Yan Zhang
Journal:  Future Med Chem       Date:  2021-02-16       Impact factor: 3.808

5.  Molecular Dynamics Simulations to Investigate How PZM21 Affects the Conformational State of the μ-Opioid Receptor Upon Activation.

Authors:  Zhennan Zhao; Tingting Huang; Jiazhong Li
Journal:  Int J Mol Sci       Date:  2020-07-01       Impact factor: 5.923

Review 6.  The Mechanisms Involved in Morphine Addiction: An Overview.

Authors:  Joanna Listos; Małgorzata Łupina; Sylwia Talarek; Antonina Mazur; Jolanta Orzelska-Górka; Jolanta Kotlińska
Journal:  Int J Mol Sci       Date:  2019-09-03       Impact factor: 5.923

7.  Pharmacological Characterization of µ-Opioid Receptor Agonists with Biased G Protein or β-Arrestin Signaling, and Computational Study of Conformational Changes during Receptor Activation.

Authors:  Justyna Piekielna-Ciesielska; Roberto Artali; Ammar A H Azzam; David G Lambert; Alicja Kluczyk; Luca Gentilucci; Anna Janecka
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

Review 8.  Structural Insights into Ligand-Receptor Interactions Involved in Biased Agonism of G-Protein Coupled Receptors.

Authors:  Krzysztof Jóźwiak; Anita Płazińska
Journal:  Molecules       Date:  2021-02-06       Impact factor: 4.411

Review 9.  Insights From Molecular Dynamics Simulations of a Number of G-Protein Coupled Receptor Targets for the Treatment of Pain and Opioid Use Disorders.

Authors:  João Marcelo Lamim Ribeiro; Marta Filizola
Journal:  Front Mol Neurosci       Date:  2019-08-23       Impact factor: 5.639

Review 10.  Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.

Authors:  Joaquim Azevedo Neto; Anna Costanzini; Roberto De Giorgio; David G Lambert; Chiara Ruzza; Girolamo Calò
Journal:  Molecules       Date:  2020-08-25       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.